Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen of the people involved rather than any candidates in the pipeline.
Celgene spin-off, Celularity, would argue that it has both but, it has to be said, the brains behind the business are particularly impressive and that could be why it managed to raise $250 million in an extended Series A financing round.
